I-Mab announced the publication of first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer Research. This journal is a highly-ranked clinical oncology publication of the American Association for Cancer Research.
The paper detailed promising clinical data, showing that givastomig monotherapy achieved an objective response rate (ORR) of 16% (7/43 patients) in heavily pretreated Claudin 18.2-positive gastric cancer patients. After the data cutoff, two additional patients were enrolled, increasing the ORR to 18% (8/45 patients).
Givastomig monotherapy was observed to be well tolerated, demonstrating single-agent activity across a wide range of Claudin 18.2 expression levels, with a 9.4-month median duration of response. The molecular design, with silenced Fc effector function, contributed to less gastrointestinal toxicity compared to other Claudin 18.2 assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.